{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=47",
    "query": {
      "intervention": "Open Label Extension Study",
      "page": 47
    },
    "page_size": 10
  },
  "pagination": {
    "page": 47,
    "page_size": 10,
    "total_count": 2083,
    "total_pages": 209,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=48&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=46&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T10:30:05.165Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01264679",
      "title": "A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Iron Deficiency Anemia"
      ],
      "interventions": [
        {
          "name": "Ferumoxytol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AMAG Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 8,
      "start_date": "2011-12-27",
      "completion_date": "2015-04-24",
      "has_results": true,
      "last_update_posted_date": "2022-04-28",
      "last_synced_at": "2026-11-04T10:30:05.165Z",
      "location_count": 1,
      "location_summary": "Waltham, Massachusetts",
      "locations": [
        {
          "city": "Waltham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01264679"
    },
    {
      "nct_id": "NCT06910813",
      "title": "DFT383 in Pediatric Participants With Nephropathic Cystinosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Nephropathic Cystinosis"
      ],
      "interventions": [
        {
          "name": "DFT383",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "2 Years to 5 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-06-02",
      "completion_date": "2044-05-28",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-04T10:30:05.165Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • San Diego, California • Stanford, California + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06910813"
    },
    {
      "nct_id": "NCT04041284",
      "title": "A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine",
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Fremanezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 353,
      "start_date": "2019-09-13",
      "completion_date": "2022-08-31",
      "has_results": true,
      "last_update_posted_date": "2023-10-02",
      "last_synced_at": "2026-11-04T10:30:05.165Z",
      "location_count": 17,
      "location_summary": "Little Rock, Arkansas • San Diego, California • Denver, Colorado + 14 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04041284"
    },
    {
      "nct_id": "NCT01886378",
      "title": "A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)",
        "Carnitine Palmitoyltransferase (CPT II) Deficiency",
        "Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency",
        "Longchain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency",
        "Trifunctional Protein (TFP) Deficiency"
      ],
      "interventions": [
        {
          "name": "UX007",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 29,
      "start_date": "2014-02-06",
      "completion_date": "2016-08-25",
      "has_results": true,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-11-04T10:30:05.165Z",
      "location_count": 7,
      "location_summary": "Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01886378"
    },
    {
      "nct_id": "NCT07436689",
      "title": "Long-Term Open-Label Extension Study of Oral Levosimendan",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Hypertension Associated With HFpEF"
      ],
      "interventions": [
        {
          "name": "TNX-103",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tenax Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2026-03-13",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-11-04T10:30:05.165Z",
      "location_count": 10,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 7 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07436689"
    },
    {
      "nct_id": "NCT04512235",
      "title": "A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "AL Amyloidosis"
      ],
      "interventions": [
        {
          "name": "CAEL-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 281,
      "start_date": "2020-11-03",
      "completion_date": "2027-04-08",
      "has_results": true,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-11-04T10:30:05.165Z",
      "location_count": 32,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Palo Alto, California + 26 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04512235"
    },
    {
      "nct_id": "NCT03052725",
      "title": "A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophils, Asthma"
      ],
      "interventions": [
        {
          "name": "reslizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 391,
      "start_date": "2017-03-10",
      "completion_date": "2018-02-22",
      "has_results": true,
      "last_update_posted_date": "2022-12-14",
      "last_synced_at": "2026-11-04T10:30:05.165Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Huntington Beach, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Napa",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03052725"
    },
    {
      "nct_id": "NCT01311648",
      "title": "BAY81-8973 Pediatric Safety and Efficacy Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Haemophilia A"
      ],
      "interventions": [
        {
          "name": "Recombinant Factor VIII (Kovaltry, BAY81-8973)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "12 Years",
        "sex": "MALE",
        "summary": "0 Years to 12 Years · Male only"
      },
      "enrollment_count": 94,
      "start_date": "2011-06-09",
      "completion_date": "2020-10-27",
      "has_results": true,
      "last_update_posted_date": "2023-12-05",
      "last_synced_at": "2026-11-04T10:30:05.165Z",
      "location_count": 4,
      "location_summary": "New Orleans, Louisiana • Cincinnati, Ohio • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01311648"
    },
    {
      "nct_id": "NCT02143843",
      "title": "An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Open-Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Bimatoprost",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ForSight Vision5, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2014-06-05",
      "completion_date": "2016-01-31",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-11-04T10:30:05.165Z",
      "location_count": 10,
      "location_summary": "Artesia, California • La Jolla, California • Newport Beach, California + 7 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02143843"
    },
    {
      "nct_id": "NCT01961921",
      "title": "The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "TTR-mediated Amyloidosis"
      ],
      "interventions": [
        {
          "name": "ALN-TTR02 (patisiran) administered by intravenous (IV) infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 27,
      "start_date": "2013-10",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2024-04-19",
      "last_synced_at": "2026-11-04T10:30:05.165Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01961921"
    }
  ]
}